What is Biorestorative Therapies Inc's earnings per share (EPS)?

Biorestorative Therapies Inc (BRTX) reported diluted earnings per share of -$1.58 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Biorestorative Therapies Inc Financials

BRTX

FY2025 annual

Revenue $360K -10.3% YoY

Net Income -$14.2M -58.6% YoY

EPS (Diluted) -$1.58 YoY not available

Free Cash Flow -$10.9M -30.8% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 14, 2026 Currency USD FYE December

Biorestorative Therapies Inc (BRTX) reported $360K in revenue for fiscal year 2025, down 10.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BRTX FY2025 2026-08-26

Development spending is rising faster than commercialization, while shrinking assets and equity funding reshape the company’s financial mechanics.

FY2025 revenue declined 10.3% while R&D reached $10.1M, indicating spending intensity—not sales volume—is driving the operating model. Gross margin held at 93.4% as net loss widened to $14.2M, so deterioration came below production economics, where development costs overwhelmed the small revenue base.

By FY2025, total assets had contracted to $4.1M while liabilities stood at $3.7M, leaving little balance-sheet cushion. The current ratio fell to 0.8x from 3.0x in FY2024, meaning short-term obligations exceeded current assets; this is a liquidity tightening, not merely a larger reported loss.

Operating cash flow of -$10.8M nearly matched free cash flow of -$10.9M, showing that the accounting loss was accompanied by a similar cash requirement rather than being mostly non-cash. Shares outstanding increased 28.3% from FY2024 while financing cash flow was $2.9M, linking the funding pattern to equity-related financing as internal cash generation remained negative.

Financial Health Signals

Financial health score not available

Biorestorative Therapies Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-70.23

Biorestorative Therapies Inc scores -70.23, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.1M) relative to total liabilities ($3.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Biorestorative Therapies Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Biorestorative Therapies Inc reported a net loss of $14.2M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Biorestorative Therapies Inc reported an operating loss of $15.6M against $266K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$360K

YoY-10.3%

5Y CAGR+36.1%

10Y CAGR-5.4%

Biorestorative Therapies Inc generated $360K in revenue in fiscal year 2025. This represents a decrease of 10.3% from the prior year.

EBITDA

-$15.4M

YoY-35.8%

Biorestorative Therapies Inc's EBITDA was -$15.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 35.8% from the prior year.

Net Income

-$14.2M

YoY-58.6%

Biorestorative Therapies Inc reported -$14.2M in net income in fiscal year 2025. This represents a decrease of 58.6% from the prior year.

EPS (Diluted)

-$1.58

Biorestorative Therapies Inc earned -$1.58 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$10.9M

YoY-30.8%

Biorestorative Therapies Inc recorded an outflow of $10.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 30.8% from the prior year.

Cash & Debt

$1.5M

YoY+175.8%

5Y CAGR-13.2%

10Y CAGR+24.7%

Biorestorative Therapies Inc held $1.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

25M

Biorestorative Therapies Inc had 25M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

93.4%

YoY+0.4pp

Biorestorative Therapies Inc's gross margin was 93.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the prior year.

Return on Equity

-3992.2%

YoY-3887.0pp

Biorestorative Therapies Inc's ROE was -3992.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 3887.0 percentage points from the prior year.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$10.1M

YoY+50.5%

5Y CAGR+63.0%

10Y CAGR+17.0%

Biorestorative Therapies Inc invested $10.1M in research and development in fiscal year 2025. This represents an increase of 50.5% from the prior year.

Share Buybacks

Biorestorative Therapies Inc repurchased no shares in fiscal year 2025.

Capital Expenditures

$116K

YoY+9.3%

Biorestorative Therapies Inc invested $116K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 9.3% from the prior year.

BRTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BRTX quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$358K	$360K-10.3%	$401K+175.0%	$146K+21.7%	$120K+160.4%	$46K-40.3%	$77K-40.8%	$130K+17.1%	$111K+37.0%	$81K+122.8%	$36K-94.2%	$629K+51.2%	$416K+24661.7%	$2K-89.2%	$16K	$0
Cost of Revenue	$28K	$24K-15.1%	$28K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$102-100.0%	$262K+22.3%	$214K+102704.8%	$208-84.1%	$1K	$0
Gross Profit	$330K	$336K-9.9%	$373K+155.8%	$146K	N/A	N/A	N/A	N/A	N/A	$81K+123.4%	$36K-90.1%	$367K+81.7%	$202K+13633.8%	$1K-89.7%	$14K	$0
R&D Expenses	$9.4M	$10.1M+50.5%	$6.7M+66.2%	$4.0M+14.8%	$3.5M+381.9%	$729K-16.9%	$877K-49.1%	$1.7M+13.8%	$1.5M-29.7%	$2.2M-25.4%	$2.9M+37.0%	$2.1M+47.1%	$1.4M-10.3%	$1.6M+110.6%	$757K+6206.5%	$12K
SG&A Expenses	$5.2M	$5.9M+12.8%	$5.2M-53.9%	$11.3M-27.3%	$15.6M-39.2%	$25.6M+1334.2%	$1.8M-61.2%	$4.6M+14.5%	$4.0M+3.1%	$3.9M+20.3%	$3.2M-16.1%	$3.9M+71.4%	$2.3M-0.3%	$2.3M-23.3%	$3.0M	N/A
Operating Income	-$14.2M	-$15.6M-35.4%	-$11.6M+24.1%	-$15.2M+19.8%	-$19.0M+27.9%	-$26.3M-855.9%	-$2.8M	N/A	N/A	-$8.4M-7.6%	-$7.8M-8.6%	-$7.2M-45.7%	-$4.9M-3.6%	-$4.8M+14.7%	-$5.6M	N/A
Interest Expense	N/A	$266K-56.8%	$616K+11.5%	$552K+4640.7%	$12K+100.6%	-$1.8M	N/A	N/A	N/A	$208K+2048.9%	$10K-96.3%	$264K-7.6%	$285K-23.2%	$371K-37.3%	$592K+127.6%	$260K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	N/A	N/A
Net Income	-$11.1M	-$14.2M-58.6%	-$9.0M+13.8%	-$10.4M+21.2%	-$13.2M+70.2%	-$44.3M-293.0%	-$11.3M	N/A	N/A	N/A	N/A	-$7.9M-41.8%	-$5.6M+2.8%	-$5.8M	N/A	N/A
EPS (Diluted)	—	-$1.58	-$1.16	-$2.47+32.3%	-$3.65	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$23K+18.2%	$20K+66.1%	$12K-96.1%	$303K+1113.2%	$25K-42.3%	$43K-81.5%	$234K+162.2%	$89K
Cost of Revenue	$7K+351.4%	$2K-84.5%	$11K+21.1%	$9K+200.1%	$3K	N/A	$18K+181.1%	$6K
Gross Profit	$16K-12.1%	$18K+1360.5%	$1K-99.6%	$295K+1233.4%	$22K-44.7%	$40K-81.4%	$215K+160.7%	$83K
R&D Expenses	$1.9M-26.7%	$2.6M+1.2%	$2.6M+16.6%	$2.2M-15.9%	$2.6M-3.4%	$2.7M+88.6%	$1.5M0.0%	$1.5M
SG&A Expenses	$1.5M+21.3%	$1.2M+9.0%	$1.1M-18.8%	$1.4M-37.1%	$2.2M+19388.8%	-$11K-101.1%	$1.0M-4.4%	$1.1M
Operating Income	-$3.4M+11.5%	-$3.8M-3.1%	-$3.7M-12.2%	-$3.3M+31.2%	-$4.8M-78.7%	-$2.7M-17.6%	-$2.3M+7.4%	-$2.5M
Interest Expense	N/A	$35K-40.1%	$58K-21.9%	$74K-26.1%	$100K-16.0%	$119K-25.0%	$159K-9.9%	$176K
Net Income	-$2.2M+32.8%	-$3.2M-5.6%	-$3.0M-14.4%	-$2.7M+50.3%	-$5.3M-226.4%	-$1.6M-49.9%	-$1.1M+72.9%	-$4.0M
EPS (Diluted)	-$0.12	-$0.32	-$0.33-10.0%	-$0.30+53.1%	-$0.64-220.0%	-$0.20-53.8%	-$0.13+74.0%	-$0.50

Not reported in any period shown, so not listed: Income Tax.

BRTX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BRTX quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$4.1M-66.8%	$12.3M-2.6%	$12.6M-23.3%	$16.4M-26.8%	$22.5M+416.5%	$4.3M+196.5%	$1.5M+23.0%	$1.2M-32.2%	$1.8M+11.3%	$1.6M-21.7%	$2.0M+19.2%	$1.7M+22.3%	$1.4M+9.1%	$1.3M+473.8%	$221K
Current Assets	$3.1M-71.9%	$11.1M-2.2%	$11.4M-24.7%	$15.1M-29.5%	$21.5M+573.6%	$3.2M+4528.1%	$69K-62.0%	$181K-65.2%	$520K+608.1%	$73K-74.6%	$289K+153.1%	$114K-52.3%	$240K+666.6%	$31K-73.6%	$118K
Cash & Equivalents	$1.5M+175.8%	$548K-38.0%	$884K-48.4%	$1.7M-91.8%	$21.0M+586.1%	$3.1M+184071.3%	$2K-98.6%	$118K-74.0%	$452K+1319.4%	$32K-80.9%	$167K+81.4%	$92K-54.4%	$201K+55298.9%	$363-99.5%	$72K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2K-89.2%	$18K+43.9%	$12K	$0
Accounts Receivable	$16K-91.8%	$188K+876.2%	$19K+20.6%	$16K+220.0%	$5K-70.6%	$17K-46.9%	$32K+10.3%	$29K-23.7%	$38K+533.3%	$6K-93.6%	$93K	$0	N/A	N/A	N/A
Total Liabilities	$3.7M-0.7%	$3.7M+43.8%	$2.6M-57.6%	$6.1M-47.4%	$11.7M+105.5%	$5.7M-60.1%	$14.2M+44.8%	$9.8M+14.4%	$8.6M+30.6%	$6.6M+11.1%	$5.9M-30.9%	$8.6M+6.3%	$8.1M+25.9%	$6.4M+64.0%	$3.9M
Current Liabilities	$3.7M-0.7%	$3.7M+43.8%	$2.6M-56.4%	$6.0M+1544.2%	$364K-65.2%	$1.0M-92.4%	$13.7M+48.3%	$9.3M+10.8%	$8.4M+42.9%	$5.8M+4.1%	$5.6M-34.2%	$8.5M+13.6%	$7.5M+166.4%	$2.8M-27.9%	$3.9M
Long-Term Debt	N/A	N/A	N/A	N/A	$250K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$357K-95.8%	$8.5M-14.7%	$10.0M-2.8%	$10.3M-4.6%	$10.8M+909.8%	-$1.3M+89.6%	-$12.8M-47.9%	-$8.6M-26.4%	-$6.8M-36.7%	-$5.0M-27.9%	-$3.9M+43.3%	-$6.9M-3.0%	-$6.7M-30.0%	-$5.1M-39.5%	-$3.7M
Retained Earnings	-$169.9M-9.1%	-$155.7M-6.1%	-$146.7M-7.6%	-$136.3M-1.6%	-$134.1M-49.3%	-$89.8M-14.3%	-$78.6M-22.9%	-$63.9M-24.4%	-$51.4M-22.5%	-$42.0M-25.9%	-$33.3M-31.2%	-$25.4M-28.2%	-$19.8M	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$4.6M+13.7%	$4.1M-27.7%	$5.6M-33.7%	$8.5M-17.5%	$10.3M-15.9%	$12.3M-15.7%	$14.6M-9.6%	$16.1M
Current Assets	$3.8M+21.1%	$3.1M-33.4%	$4.7M-38.0%	$7.6M-18.8%	$9.4M-16.1%	$11.1M-17.5%	$13.5M-10.0%	$15.0M
Cash & Equivalents	$3.1M+106.0%	$1.5M+150.8%	$602K-61.3%	$1.6M+26.6%	$1.2M+124.3%	$548K-63.2%	$1.5M-33.9%	$2.3M
Accounts Receivable	$13K-14.2%	$16K+15.7%	$13K-10.7%	$15K-40.0%	$25K-86.7%	$188K+14.2%	$165K+502.2%	$27K
Total Liabilities	$1.6M-56.6%	$3.7M+8.4%	$3.4M-6.4%	$3.7M-12.2%	$4.2M+11.6%	$3.7M-18.2%	$4.6M-13.9%	$5.3M
Current Liabilities	$1.6M-56.6%	$3.7M+8.4%	$3.4M-6.4%	$3.7M-12.2%	$4.2M+11.6%	$3.7M-18.2%	$4.6M-13.9%	$5.3M
Total Equity	$3.0M+748.1%	$357K-83.8%	$2.2M-54.5%	$4.8M-21.1%	$6.1M-28.0%	$8.5M-14.6%	$10.0M-7.5%	$10.8M
Retained Earnings	-$172.1M-1.3%	-$169.9M-1.9%	-$166.7M-1.9%	-$163.7M-1.6%	-$161.0M-3.4%	-$155.7M-1.1%	-$154.0M-0.7%	-$153.0M

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

BRTX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BRTX quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$11.8M	-$10.8M-31.1%	-$8.2M-28.0%	-$6.4M-8.7%	-$5.9M-77.6%	-$3.3M-69.5%	-$2.0M+71.6%	-$6.9M-35.5%	-$5.1M-32.5%	-$3.9M+23.0%	-$5.0M-60.2%	-$3.1M+3.3%	-$3.2M-20.8%	-$2.7M+16.1%	-$3.2M	N/A
Capital Expenditures	N/A	$116K+9.3%	$106K-37.9%	$171K-35.5%	$265K+765.1%	$31K	N/A	$36K+176.9%	$13K+255.8%	$4K-98.1%	$189K-53.7%	$408K+142.4%	$168K+1408.7%	$11K+340.6%	$3K-85.7%	$18K
Free Cash Flow	N/A	-$10.9M-30.8%	-$8.3M-26.3%	-$6.6M-6.8%	-$6.2M-83.8%	-$3.4M	N/A	-$7.0M-35.9%	-$5.1M-32.7%	-$3.9M+25.7%	-$5.2M-47.1%	-$3.5M-3.9%	-$3.4M-26.6%	-$2.7M+15.8%	-$3.2M	N/A
Investing Cash Flow	$7.5M	$8.9M+1629.2%	$515K-84.2%	$3.3M+124.3%	-$13.4M-43607.5%	-$31K	N/A	-$36K-176.9%	-$13K-255.8%	-$4K	N/A	N/A	N/A	-$11K+98.9%	-$1.0M-7146.2%	$14K
Financing Cash Flow	$6.2M	$2.9M-61.3%	$7.4M+214.2%	$2.3M	N/A	$21.3M+324.1%	$5.0M-26.5%	$6.8M+43.0%	$4.8M+11.8%	$4.3M	N/A	N/A	N/A	$2.9M-29.9%	$4.1M	N/A
Share Buybacks	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$4K

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$3.8M-57.7%	-$2.4M+16.8%	-$2.9M-7.7%	-$2.7M+3.1%	-$2.8M-18.4%	-$2.3M-38.1%	-$1.7M+8.9%	-$1.9M
Capital Expenditures	N/A	$80K	$0	$0-100.0%	$36K+192.7%	$12K-78.7%	$58K	N/A
Free Cash Flow	N/A	-$2.5M+14.0%	-$2.9M-7.7%	-$2.7M+4.3%	-$2.8M-19.3%	-$2.4M-34.3%	-$1.8M	N/A
Investing Cash Flow	$968K-59.7%	$2.4M+20.2%	$2.0M-6.3%	$2.1M-9.9%	$2.4M+54.4%	$1.5M+63.6%	$937K-68.5%	$3.0M
Financing Cash Flow	$4.4M+381.0%	$923K+1972.4%	-$49K-105.6%	$888K-18.7%	$1.1M+965.1%	-$126K	$0+100.0%	-$13K
Share Buybacks	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Dividends Paid.

BRTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

BRTX quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	93.4%+0.4pp	93.0%-7.0pp	100.0%	N/A	N/A	N/A	N/A	N/A	100.0%+0.3pp	99.7%+41.3pp	58.4%+9.8pp	48.6%-39.0pp	87.6%-4.0pp	91.6%	N/A
Operating Margin	-4350.1%	-2881.6%	-10439.5%	-15838.1%	-57191.0%	-3574.1%	N/A	N/A	-10338.6%	-21414.0%	-1140.1%	-1183.3%	-282873.2%	-35746.1%	N/A
Net Margin	-3959.4%	-2239.3%	-7145.2%	-11037.0%	-96311.5%	-14639.9%	N/A	N/A	N/A	N/A	-1259.9%	-1343.2%	-342333.0%	N/A	N/A
Return on Equity	-3992.2%-3887.0pp	-105.3%-1.1pp	-104.1%+24.4pp	-128.5%+282.4pp	-410.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-349.1%-276.0pp	-73.1%+9.5pp	-82.6%-2.1pp	-80.5%+116.9pp	-197.3%+62.0pp	-259.3%	N/A	N/A	N/A	N/A	-392.8%-62.6pp	-330.3%+85.6pp	-415.9%	N/A	N/A
Current Ratio	0.84-2.1x	2.97-1.4x	4.37+1.8x	2.53-56.5x	59.01+56.0x	3.05+3.0x	0.010.0x	0.020.0x	0.060.0x	0.010.0x	0.050.0x	0.010.0x	0.030.0x	0.010.0x	0.03
Debt-to-Equity	10.44+10.0x	0.44+0.2x	0.26-0.3x	0.60+0.6x	0.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	-3031.7%	-2078.9%	-4527.6%	-5157.2%	-7305.6%	N/A	-5349.5%	-4610.4%	-4762.3%	-14279.8%	-561.3%	-816.4%	-159736.0%	-20441.6%	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	68.1%-23.5pp	91.6%+81.2pp	10.4%-86.7pp	97.1%+8.8pp	88.4%-3.9pp	92.3%+0.1pp	92.2%-0.5pp	92.7%
Operating Margin	-14612.6%	-19516.8%	-31432.3%	-1089.8%	-19230.1%	-6212.8%	-979.0%	-2770.8%
Net Margin	-9298.3%	-16365.5%	-25748.1%	-875.8%	-21359.2%	-3778.6%	-467.2%	-4521.4%
Return on Equity	-71.2%+827.9pp	-899.1%-761.5pp	-137.7%-82.8pp	-54.8%+32.1pp	-86.9%-67.7pp	-19.2%-8.3pp	-10.9%+26.4pp	-37.3%
Return on Assets	-46.4%+32.2pp	-78.6%-24.8pp	-53.8%-22.6pp	-31.2%+20.5pp	-51.7%-38.4pp	-13.3%-5.8pp	-7.5%+17.5pp	-25.0%
Current Ratio	2.35+1.5x	0.84-0.5x	1.37-0.7x	2.07-0.2x	2.24-0.7x	2.970.0x	2.95+0.1x	2.82
Debt-to-Equity	0.53-9.9x	10.44+8.9x	1.56+0.8x	0.76+0.1x	0.68+0.2x	0.440.0x	0.460.0x	0.49
FCF Margin	N/A	-12728.8%	-24585.9%	-888.2%	-11260.7%	-5451.0%	-752.6%	N/A

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: The current ratio is below 1.0 (0.84), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Aptorum Group Ltd APM

$570K

Xtl Biopharmaceu XTLB

$6.1M

Briacell Therapeutics Corp BCTX

$32.5M

Biovie Inc BIVI

$18.3M

Biomx Inc PHGE

$3.7M

Where Biorestorative Therapies Inc Ranks

Frequently Asked Questions

What is Biorestorative Therapies Inc's annual revenue?

Biorestorative Therapies Inc (BRTX) reported $360K in total revenue for fiscal year 2025. This represents a -10.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Biorestorative Therapies Inc's revenue growing?

Biorestorative Therapies Inc (BRTX) revenue declined by 10.3% year-over-year, from $401K to $360K in fiscal year 2025.

Is Biorestorative Therapies Inc profitable?

No, Biorestorative Therapies Inc (BRTX) reported a net income of -$14.2M in fiscal year 2025.

What is Biorestorative Therapies Inc's EBITDA?

Biorestorative Therapies Inc (BRTX) had EBITDA of -$15.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Biorestorative Therapies Inc's gross margin?

Biorestorative Therapies Inc (BRTX) had a gross margin of 93.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Biorestorative Therapies Inc's return on equity (ROE)?

Biorestorative Therapies Inc (BRTX) has a return on equity of -3992.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Biorestorative Therapies Inc's free cash flow?

Biorestorative Therapies Inc (BRTX) recorded an outflow of $10.9M in free cash flow during fiscal year 2025. This represents a -30.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Biorestorative Therapies Inc's operating cash flow?

Biorestorative Therapies Inc (BRTX) recorded an outflow of $10.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Biorestorative Therapies Inc's total assets?

Biorestorative Therapies Inc (BRTX) had $4.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Biorestorative Therapies Inc's capital expenditures?

Biorestorative Therapies Inc (BRTX) invested $116K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Biorestorative Therapies Inc spend on research and development?

Biorestorative Therapies Inc (BRTX) invested $10.1M in research and development during fiscal year 2025.

How many shares does Biorestorative Therapies Inc have outstanding?

Biorestorative Therapies Inc (BRTX) had 25M shares outstanding as of fiscal year 2025.

What is Biorestorative Therapies Inc's current ratio?

Biorestorative Therapies Inc (BRTX) had a current ratio of 0.84 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Biorestorative Therapies Inc's debt-to-equity ratio?

Biorestorative Therapies Inc (BRTX) had a debt-to-equity ratio of 10.44 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Biorestorative Therapies Inc's return on assets (ROA)?

Biorestorative Therapies Inc (BRTX) had a return on assets of -349.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Biorestorative Therapies Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Biorestorative Therapies Inc (BRTX) held $3.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.8M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Biorestorative Therapies Inc's Altman Z-Score?

Biorestorative Therapies Inc (BRTX) has an Altman Z-Score of -70.23, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Biorestorative Therapies Inc's Piotroski F-Score?

Biorestorative Therapies Inc (BRTX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biorestorative Therapies Inc's earnings high quality?

Biorestorative Therapies Inc (BRTX) reported a net loss of $14.2M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Biorestorative Therapies Inc cover its interest payments?

Biorestorative Therapies Inc (BRTX) reported an operating loss of $15.6M against $266K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.